Table 1. Characteristics of CML patients at diagnosis in chronic phase.
| AgeMedian (range) | 53 (22–73) |
| SexMales/Females | 25/15 |
| Sokal risk scoreLowIntermediateHigh | 14 (36%)16 (39%)10 (25%) |
| Response at 3 moCHR/<CHR/noCHR1 | 18/14/8 |
| Response at 6 moCCgR or PCgR/<PCgR/no CgR1 | 28/10/4 |
| Response at 12 moCCgR or PCgR/<PCgR/no CgR1CMoR/MMoR1 | 32/4/45/14 |
1
CHR: complete hematologic response (normalization of peripheral blood count and no palpable spleen); CCgR: complete cytogenetic response (Ph+ none); PCgR: partial cytogenetic response (Ph+ 1–35%); no CgR: no cytogenetical response (Ph+>95%); <:less than; <PCgR include minor (Ph+ 36%–66%) and minimal (Ph+66–90%); CMoR: complete molecular response (transcript non-detectable); MMoR: major molecular response (<0.1%). All these definitions of the clinical response have been assigned according to the European LeukemiaNet. (Numbers in bold: non responder patients, i.e. no CHR, no CgR at 3 and 6 mo; these patients underwent imatinib 800 mg/daily after 6 mo and nilotinib or dasatinib after 12 mo).